Search PubMed⌕ Search

Biomedical subjects

L Hansson

Publications and source records attributed to L Hansson.

565 records · Page 32Linked to original sources
PubMedDate not supplied

1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization.

The present Guidelines were prepared by the Guidelines Sub-Committee of the World Health Organization-International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee, the members of which are listed at the end of the text. These guidelines represent the fourth revision of the WHO-ISH Guidelines and were finalised after presentation and discussion at the 7th WHO-ISH Meeting on Hypertension, Fukuoka, Japan, 29th Sept-1st Oct, 1998. Previous versions of the Guidelines were published in Bull WHO 1993, 71:503-517 and J Hypertens 1993, 11:905-918.

Adult↗
PubMedDate not supplied

Adrenergic agents: clinical trials and experiences.

Beta-adrenergic blocking agents constitute first-line therapy for hypertension in many countries of the world. Comparative trials have been extensive in duration and have included large numbers of patients. Still, the desired cardioprotective effect of beta blockers has yet to be established. Their antiatherosclerotic effect has been noted in several animal experiments. Confirming evidence is needed before the clinical relevance of this effect can be evaluated, but these studies point to a potential therapeutic effect that may be immensely important in the future. Beta blockers can reverse left ventricular hypertrophy secondary to hypertension, but it remains to be shown that regression of left ventricular hypertrophy will reduce the associated risks.

Adrenergic beta-Antagonists↗
PubMedDate not supplied

Influence of gender on prevention of myocardial infarction by antihypertensives and acetylsalicylic acid: the HOT study.

OBJECTIVE: The aims of the Hypertension Optimal Treatment (HOT) Study were to investigate the relationship between three levels of target office diastolic blood pressure (BP; < or = 90, < or = 85, and < or = 80 mm Hg) and cardiovascular death, myocardial infarction (MI), and stroke in hypertensive patients, and to examine the effects of 75 mg of acetylsalicylic acid (ASA) daily versus placebo. DESIGN: Randomized, double-blind study. This substudy assessed the influence of gender on the incidence of MI. SUBJECTS: A total of 18,790 patients (mean age, 61.5 years; range, 50-80 years). METHODS: Patients were randomized and followed for an average of 3.8 years until 71,051 patient-years had elapsed and 683 events, including 215 MIs, had occurred. RESULTS: There were significantly fewer MIs in the lowest diastolic BP target group (P = .034) in women (n = 8883); a similar but smaller trend was not statistically significant in men. The effect of ASA on preventing MI was also influenced by gender (P = .38 in women; P = .001 in men [lowered by 42%]). CONCLUSION: Lowering diastolic BP to about 80 mm Hg in hypertensive women and administering 75 mg of ASA daily to well-treated hypertensive men reduces MI in patients with essential hypertension.

Aged↗